Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer

International Journal of Urology

Volumn 5, Issue 1, 1998, Pages 44-47

  Nishiyama, Tsutomu ^a,b   Terunuma, Masahiro ^a  

^a Nagaoka Chuo General Hospital   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

Dexamethasone; Hormone withdrawal; Prostate cancer; Prostate specific antigen

Indexed keywords

ALKYLATING AGENT; ANTIANDROGEN; CHLORMADINONE ACETATE; DEXAMETHASONE; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DRUG WITHDRAWAL; HUMAN; MALE; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031929708     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00233.x     Document Type: Article

References (19)

1. Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
3. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607-609.
4. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572.
5. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for antiandrogen withdrawal syndrome. Urology 1994;43:408-410.
6. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995; 153:1944-1945.
7. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995;153: 1946-1947.
8. Huggins C, Scott WW. Bilateral adrenalectomy of prostatic cancer; clinical features and urinary excretion of 17-ketosteroids and estrogens. Ann Surg 1945;122:1031-1041.
9. Stahl F, Schnorr D, Bar CM, Frohlich G, Dorner G. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and dexamethasone in patients with prostatic cancer. Exp Clin Endocrinol 1989;94:239-243.
10. Williams G, Asopa R, Abel PD, Smith C. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol 1990;65:504-508.
11. Japanese Urological Association and the Japanese Pathological Society. General rules for clinical and pathological studies on prostatic cancer. 2nd ed. Tokyo: Kanehara, 1992:9-106.
12. Nishiyama T, Terunuma M. Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report. Int J Urol 1994;1: 355-356.
13. Akakura K, Akimoto S, Ohki T, Shimazaki J. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 1995;45:700-704.
14. Sekido N, Kawai K, Akaza H, Koiso K. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer. Jpn J Clin Oncol 1995;25:164-167.
15. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47:61-69.
16. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173:534-540.
17. Kirschenbaum A, Ren M, Levine AC. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 1993; 58:439-444.
18. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:2,142-148.
19. Storlie JA, Buckner JC, Wiseman JA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostatic carcinoma. Cancer 1995; 76:96-100.